Ascletis Pharma Inc. (FRA:2VJ)
Germany · Delayed Price · Currency is EUR 1.390
-0.030 (-2.11%)
At close: Jan 30, 2026
Ascletis Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -258.57 | -300.94 | -144.72 | -314.84 | -199.02 | -209.24 |
Depreciation & Amortization | 17.98 | 18.86 | 16.78 | 28.4 | 27.83 | 25.77 |
Other Amortization | 1.89 | 1.89 | 3.42 | 2.11 | 2.14 | 1.84 |
Loss (Gain) From Sale of Assets | 0.34 | 0.34 | -0.09 | 0 | - | 0.09 |
Asset Writedown & Restructuring Costs | 10.58 | 10.58 | - | 55.19 | - | 5.77 |
Loss (Gain) From Sale of Investments | 25.25 | 25.25 | - | - | - | - |
Loss (Gain) on Equity Investments | -15.87 | -15.87 | -40.31 | 22.89 | 17.88 | 13.75 |
Stock-Based Compensation | 3 | 3 | 1.33 | 3.19 | 7.13 | 4.61 |
Provision & Write-off of Bad Debts | -0 | -0 | -0 | -0.01 | 0.01 | -0.08 |
Other Operating Activities | -109.54 | -98.48 | -94.67 | -33.2 | 7.27 | 62.07 |
Change in Accounts Receivable | 5.28 | 5.28 | 18.44 | 29.74 | -26.99 | 42.98 |
Change in Inventory | -3.6 | -3.6 | -8.05 | -12.84 | -5.07 | -18.37 |
Change in Accounts Payable | -0.62 | -0.62 | -2.49 | 2.08 | 0.12 | -5.71 |
Change in Unearned Revenue | -1.59 | -1.59 | -1.59 | -1.59 | -2.61 | -1.72 |
Change in Other Net Operating Assets | 14.31 | 14.31 | 28.14 | 16.41 | 24.37 | -6.67 |
Operating Cash Flow | -311.15 | -341.58 | -223.8 | -202.46 | -146.93 | -84.91 |
Capital Expenditures | -1.83 | -2.1 | -6.21 | -7.07 | -4.97 | -4.92 |
Sale of Property, Plant & Equipment | - | - | 0.12 | - | - | 0.01 |
Sale (Purchase) of Intangibles | -0.06 | -0.05 | -12.95 | -7.24 | -2.23 | -34.04 |
Investment in Securities | 1,483 | 853.84 | 160.73 | -1,137 | -269.78 | 170.96 |
Other Investing Activities | 140.66 | 127.22 | 87.78 | 3.32 | 2.48 | 0.29 |
Investing Cash Flow | 1,622 | 978.91 | 229.48 | -1,148 | -274.49 | 132.3 |
Long-Term Debt Repaid | - | -4.73 | -2.39 | -2.22 | -2.28 | -1.93 |
Net Debt Issued (Repaid) | -6.71 | -4.73 | -2.39 | -2.22 | -2.28 | -1.93 |
Issuance of Common Stock | 3.85 | - | - | 0.96 | - | - |
Repurchase of Common Stock | -69.46 | -98.53 | -78.96 | - | -28.69 | -19.6 |
Other Financing Activities | -0.22 | -0.24 | -0.14 | -0.16 | -0.13 | -0.14 |
Financing Cash Flow | -72.54 | -103.51 | -81.5 | -1.42 | -31.1 | -21.67 |
Foreign Exchange Rate Adjustments | -0.84 | 0.39 | 2.16 | 28.62 | -30.57 | -110.26 |
Net Cash Flow | 1,237 | 534.21 | -73.65 | -1,324 | -483.09 | -84.54 |
Free Cash Flow | -312.99 | -343.67 | -230.01 | -209.53 | -151.9 | -89.83 |
Free Cash Flow Margin | -13239.72% | -26786.75% | -406.40% | -387.38% | -197.59% | -256.66% |
Free Cash Flow Per Share | -0.32 | -0.34 | -0.21 | -0.19 | -0.14 | -0.09 |
Cash Interest Paid | 0.22 | 0.24 | 0.14 | 0.16 | 0.13 | 0.14 |
Levered Free Cash Flow | -200.01 | -208.35 | -131.07 | -114.01 | -111.93 | -90.34 |
Unlevered Free Cash Flow | -199.87 | -208.2 | -130.98 | -113.91 | -111.86 | -90.26 |
Change in Working Capital | 13.79 | 13.79 | 34.45 | 33.81 | -10.18 | 10.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.